Bile Acids: Key Regulators and Novel Treatment Targets for Type 2 Diabetes

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_center" colspan="2">Subtypes of bile acids</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">FXR agonists</td><td class="align_center">6-ECDCA<sup>43</sup> (synthetic)&gt;CDCA<sup>44,45,46</sup>&gt;CA&gt;DCA&gt;LCA</td></tr><tr><td class="align_left">FXR antagonists</td><td class="align_center">T<i>α</i>MCA, T<i>β</i>MCA<sup>47</sup></td></tr><tr><td class="align_left">TGR5 agonists</td><td class="align_center">INT-777<sup>48</sup> (a derivative of CDCA)&gt;LCA<sup>49,50</sup>&gt;DCA<sup>51</sup>&gt;CDCA&gt;CA&gt;UDCA</td></tr><tr><td class="align_left">TGR5 antagonists</td><td class="align_center">SBI-115<sup>52</sup> (synthetic)</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>The differential affinity of the subtypes of bile acids towards FXR and TGR5.</div>

Journal of Diabetes Research

tab1

Table 1

Table 1: Bile Acids: Key Regulators and Novel Treatment Targets for Type 2 Diabetes 